Document is current

Article History

Received: 8 September 2023

Accepted: 9 January 2024

First Online: 25 January 2024

Declarations

:

: The ANDEMIA study protocol was approved by the investigators’ institutional ethics committees in all participating countries [(CIV: Comité National d’Ethique des Sciences de la Vie et de la Santé de Côte d’Ivoire (105/MSHP/CNER-dk); Burkina Faso: Comité d’Ethique pour la Recherche en Santé (2017–5–057); Democratic Republic of the Congo: Comité d’Ethique de l’Ecole de Santé Publique de l’Université de Kinshasa (ESP/CE/042/2017); South Africa: Faculty of Health Research Ethic Committee (Medical), University of Witwatersrand (M170403), Faculty of Health Sciences Research Ethics Committee, University of Pretoria (101/2017); Germany: Ethikkommission - Ethikausschuss am Campus Virchow-Klinikum, Charité (EA2/230/17)]. Written informed consent was obtained from all enrolled patients or their legal guardian. Patient privacy was protected by removing all personal identifiers before entry in the database, and access to patient level data was restricted to selected study personnel.

: Not applicable.

: One author NP reported a potential competing interest as follows:NP has received contractual fees by GSK, has received grants or contracts from PATH Center for Vaccine Innovation and Access, has received support from the Defense Threat Reduction Agency for attending meetings for the Annual Biological Safety Conference, Milwaukee and has participated on the GSK Rotavirus Advisory Board. All the other authors declare that they have no competing interest.